New hope for severe eczema sufferers in clinical trial

NCT ID NCT07220577

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an experimental medication called GIA632 can help control moderate to severe eczema (atopic dermatitis). Researchers will compare GIA632 against a placebo in 84 adult participants over 16 weeks to see if it improves skin symptoms and is safe to use. This is an early-stage trial to gather initial evidence about the treatment's effectiveness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Aesthetics Skin Care Dermatologic Surgery
RECRUITING

Rockville, Maryland, 20850, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Care Access Hoboken
RECRUITING

Hoboken, New Jersey, 07030, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ctr for Dermatology Clinical Res
RECRUITING

Fremont, California, 95438, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

Pleven, 5800, Bulgaria
Novartis Investigative Site
RECRUITING

Sofia, 1202, Bulgaria
Novartis Investigative Site
RECRUITING

Sofia, 1618, Bulgaria
Novartis Investigative Site
RECRUITING

Toronto, Ontario, M5A 3R6, Canada
Novartis Investigative Site
RECRUITING

Québec, Quebec, G1W 4R4, Canada
Novartis Investigative Site
RECRUITING

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site
RECRUITING

Prague, 100 34, Czechia
Novartis Investigative Site
RECRUITING

Antony, 92160, France
Novartis Investigative Site
RECRUITING

Dijon, 21000, France
Novartis Investigative Site
RECRUITING

Martigues, 13500, France
Novartis Investigative Site
RECRUITING

Nice, 06000, France
Novartis Investigative Site
RECRUITING

Berlin, 10117, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20095, Germany
Novartis Investigative Site
RECRUITING

Mainz, 55131, Germany
Novartis Investigative Site
RECRUITING

Ipoh, Perak, 30450, Malaysia
Novartis Investigative Site
RECRUITING

George Town, Pulau Pinang, 10450, Malaysia
Novartis Investigative Site
RECRUITING

Kuala Lumpur, 59100, Malaysia
Novartis Investigative Site
RECRUITING

Gdansk, 80-546, Poland
Novartis Investigative Site
RECRUITING

Torun, 87-100, Poland
Novartis Investigative Site
RECRUITING

Warsaw, 00-872, Poland
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 169608, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 308205, Singapore

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS